Susquehanna International Group
VKTX icon

Susquehanna International Group’s Viking Therapeutics VKTX Stock Holding History

Susquehanna International Group’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23M Sell
705,809
-718,022
-50% -$23.1M ﹤0.01% 2060
2025
Q4 		$50.1M Sell
1,423,831
-675,733
-32% -$23.9M 0.01% 1363
2025
Q3 		$55.2M Buy
2,099,564
+32,913
+2% +$982K 0.01% 1273
2025
Q2 		$54.8M Buy
2,066,651
+389,847
+23% +$10.3M 0.01% 1103
2025
Q1 		$40.5M Buy
1,676,804
+643,395
+62% +$20.3M 0.01% 1158
2024
Q4 		$41.6M Sell
1,033,409
-81,696
-7% -$4.66M 0.01% 1259
2024
Q3 		$70.6M Sell
1,115,105
-289,610
-21% -$17M 0.01% 852
2024
Q2 		$74.5M Buy
1,404,715
+1,118,798
+391% +$73.3M 0.01% 741
2024
Q1 		$23.4M Buy
285,917
+136,635
+92% +$6.08M ﹤0.01% 1628
2023
Q4 		$2.78M Buy
149,282
+17,554
+13% +$230K ﹤0.01% 4705
2023
Q3 		$1.46M Buy
131,728
+33,047
+33% +$473K ﹤0.01% 5795
2023
Q2 		$1.6M Sell
98,681
-1,244,627
-93% -$26.1M ﹤0.01% 5619
2023
Q1 		$22.4M Buy
1,343,308
+522,450
+64% +$5.4M ﹤0.01% 1598
2022
Q4 		$7.72M Buy
820,858
+346,619
+73% +$1.55M ﹤0.01% 2619
2022
Q3 		$1.29M Buy
474,239
+326,442
+221% +$1.07M ﹤0.01% 5982
2022
Q2 		$427K Sell
147,797
-75,037
-34% -$186K ﹤0.01% 8653
2022
Q1 		$669K Sell
222,834
-51,368
-19% -$184K ﹤0.01% 8204
2021
Q4 		$1.26M Buy
274,202
+82,437
+43% +$462K ﹤0.01% 6655
2021
Q3 		$1.2M Sell
191,765
-63,393
-25% -$392K ﹤0.01% 7063
2021
Q2 		$1.53M Buy
255,158
+49,524
+24% +$294K ﹤0.01% 6583
2021
Q1 		$1.3M Sell
205,634
-71,820
-26% -$505K ﹤0.01% 7031
2020
Q4 		$1.56M Sell
277,454
-44,018
-14% -$267K ﹤0.01% 5649
2020
Q3 		$1.87M Buy
321,472
+52,871
+20% +$364K ﹤0.01% 4749
2020
Q2 		$1.94M Sell
268,601
-31,194
-10% -$207K ﹤0.01% 4563
2020
Q1 		$1.4M Buy
+299,795
New +$1.84M ﹤0.01% 4628
2019
Q4 		– Sell
-258,066
Closed -$1.88M – 10726
2019
Q3 		$1.77M Buy
258,066
+94,399
+58% +$701K ﹤0.01% 4453
2019
Q2 		$1.36M Buy
+163,667
New +$1.4M ﹤0.01% 4996
2019
Q1 		– Sell
-49,322
Closed -$413K – 9916
2018
Q4 		$377K Buy
+49,322
New +$590K ﹤0.01% 6577
2018
Q2 		– Sell
-315,587
Closed -$2.1M – 10495
2018
Q1 		$1.38M Buy
+315,587
New +$1.75M ﹤0.01% 4598
2017
Q4 		– Sell
-51,247
Closed -$98K – 9958
2017
Q3 		$98K Buy
+51,247
New +$58.2K ﹤0.01% 8368

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Susquehanna International Group's VKTX Position: Q1 2026 in Review

Susquehanna International Group reduced its Viking Therapeutics (VKTX) stake by 50% in Q1 2026, selling an estimated $23.1M and leaving 705,809 shares worth $23M. The position accounts for ﹤0.01% of the portfolio, ranked #2060.

Susquehanna International Group first reported a position in VKTX in Q3 2017 and has held it in 30 quarters since. The position peaked at $74.5M in Q2 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Susquehanna International Group held 705,809 shares of Viking Therapeutics worth $23M as of Q1 2026.
  • Susquehanna International Group sold 718,022 Viking Therapeutics shares in Q1 2026, an estimated $23.1M.
  • Viking Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #2060 holding.
  • Susquehanna International Group first reported a position in Viking Therapeutics in Q3 2017 and has held it in 30 quarters since.
  • Susquehanna International Group's Viking Therapeutics position peaked at $74.5M in Q2 2024.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.